GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Goldenwell Biotech Inc (OTCPK:GWLL) » Definitions » Capex-to-Revenue

Goldenwell Biotech (Goldenwell Biotech) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Goldenwell Biotech Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Goldenwell Biotech's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Goldenwell Biotech Capex-to-Revenue Historical Data

The historical data trend for Goldenwell Biotech's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Goldenwell Biotech Capex-to-Revenue Chart

Goldenwell Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
- - - -

Goldenwell Biotech Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Goldenwell Biotech's Capex-to-Revenue

For the Packaged Foods subindustry, Goldenwell Biotech's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Goldenwell Biotech's Capex-to-Revenue Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Goldenwell Biotech's Capex-to-Revenue falls into.



Goldenwell Biotech Capex-to-Revenue Calculation

Goldenwell Biotech's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.002
=0.00

Goldenwell Biotech's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Goldenwell Biotech  (OTCPK:GWLL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Goldenwell Biotech Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Goldenwell Biotech's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Goldenwell Biotech (Goldenwell Biotech) Business Description

Traded in Other Exchanges
N/A
Address
2071 Midway Drive, Twinsburg, OH, USA, 44087
Goldenwell Biotech Inc is engaged in the research and development, production and sales of health care and supplements products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
Executives
Li Yang director, 10 percent owner, officer: Treasurer C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Hua Xie director, officer: Secretary C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Shuang Liu director, 10 percent owner, officer: Chief Executive Officer C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087

Goldenwell Biotech (Goldenwell Biotech) Headlines

No Headlines